SCM Lifescience Co., LTD.   Report issue

For profit Phase 2
Founded: Incheon Korea, Republic of (2015)

Organization Overview

First Clinical Trial
2016
NCT04189432
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

SCM Lifescience Co., LTD.

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic stem cells (2 trials)

bone marrow derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Graft vs Host Disease (Phase 2)

Pancreatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2